Cannabinoids for the treatment of mental disorders

Affiliations

Comment

Sivan Mauer. Lancet Psychiatry. 2020 Feb.

. 2020 Feb;7(2):125.

doi: 10.1016/S2215-0366(19)30509-7.

¹ Department of Psychiatry, Tufts Medical Center, Boston, MA, 02111, USA. Electronic address: sivanmauer@yahoo.com.br.

No abstract available

Comment in

Cannabinoids for the treatment of mental disorders.
Feingold D, Lev-Ran S. Feingold D, et al. Lancet Psychiatry. 2020 Feb;7(2):126-127. doi: 10.1016/S2215-0366(19)30523-1. Lancet Psychiatry. 2020. PMID: 31981534 No abstract available.
Cannabinoids for the treatment of mental disorders - Author's reply.
Black N, Campbell G, Tran LT, Farrell M, Hall W, Degenhardt L. Black N, et al. Lancet Psychiatry. 2020 Feb;7(2):127-128. doi: 10.1016/S2215-0366(19)30526-7. Lancet Psychiatry. 2020. PMID: 31981535 No abstract available.

Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis.
Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, Farrell M, Degenhardt L. Black N, et al. Lancet Psychiatry. 2019 Dec;6(12):995-1010. doi: 10.1016/S2215-0366(19)30401-8. Epub 2019 Oct 28. Lancet Psychiatry. 2019. PMID: 31672337 Free PMC article.